[go: up one dir, main page]

SG11202006871YA - Combination therapy for treating or preventing cancer - Google Patents

Combination therapy for treating or preventing cancer

Info

Publication number
SG11202006871YA
SG11202006871YA SG11202006871YA SG11202006871YA SG11202006871YA SG 11202006871Y A SG11202006871Y A SG 11202006871YA SG 11202006871Y A SG11202006871Y A SG 11202006871YA SG 11202006871Y A SG11202006871Y A SG 11202006871YA SG 11202006871Y A SG11202006871Y A SG 11202006871YA
Authority
SG
Singapore
Prior art keywords
treating
combination therapy
preventing cancer
cancer
preventing
Prior art date
Application number
SG11202006871YA
Inventor
Alexander Stevenson
Original Assignee
4D Pharma Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1800927.4A external-priority patent/GB201800927D0/en
Priority claimed from GBGB1801502.4A external-priority patent/GB201801502D0/en
Priority claimed from GBGB1805941.0A external-priority patent/GB201805941D0/en
Priority claimed from GBGB1806572.2A external-priority patent/GB201806572D0/en
Priority claimed from GBGB1808628.0A external-priority patent/GB201808628D0/en
Application filed by 4D Pharma Res Ltd filed Critical 4D Pharma Res Ltd
Publication of SG11202006871YA publication Critical patent/SG11202006871YA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507Comprising a combination of two or more separate antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202006871YA 2018-01-19 2019-01-18 Combination therapy for treating or preventing cancer SG11202006871YA (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB1800927.4A GB201800927D0 (en) 2018-01-19 2018-01-19 Combination therapy for treating or preventing cancer
GBGB1801502.4A GB201801502D0 (en) 2018-01-30 2018-01-30 Combination therapy for treating or preventing cancer
GBGB1805941.0A GB201805941D0 (en) 2018-04-10 2018-04-10 Combination therapy for treating or preventing cancer
GBGB1806572.2A GB201806572D0 (en) 2018-04-23 2018-04-23 Combination therapy for treating or preventing cancer
GBGB1808628.0A GB201808628D0 (en) 2018-05-25 2018-05-25 Combination therapy for treating or preventing cancer
PCT/GB2019/050141 WO2019141996A1 (en) 2018-01-19 2019-01-18 Combination therapy for treating or preventing cancer

Publications (1)

Publication Number Publication Date
SG11202006871YA true SG11202006871YA (en) 2020-08-28

Family

ID=65228590

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202006871YA SG11202006871YA (en) 2018-01-19 2019-01-18 Combination therapy for treating or preventing cancer

Country Status (18)

Country Link
US (3) US20210060095A1 (en)
EP (1) EP3740218A1 (en)
JP (1) JP2021516216A (en)
KR (1) KR20200111183A (en)
CN (1) CN111629739A (en)
AU (1) AU2019210002A1 (en)
BR (1) BR112020014676A2 (en)
CA (1) CA3088413A1 (en)
CL (1) CL2020001888A1 (en)
CO (1) CO2020010013A2 (en)
IL (1) IL275949A (en)
MA (1) MA51613A (en)
MX (1) MX2020007671A (en)
NI (1) NI202000052A (en)
PH (1) PH12020551080A1 (en)
SG (1) SG11202006871YA (en)
TW (1) TW201938180A (en)
WO (1) WO2019141996A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023041574A1 (en) * 2021-09-14 2023-03-23 4D Pharma Research Limited Compositions comprising bacterial strains
WO2023041203A1 (en) * 2021-09-14 2023-03-23 4D Pharma Research Limited Compositions comprising bacterial strains
CN113995835A (en) * 2021-10-09 2022-02-01 山东新创生物科技有限公司 Application of Clostridium gordonii spore combined with PD-1 antibody
WO2023072968A1 (en) * 2021-10-25 2023-05-04 4D Pharma Research Ltd Compositions comprising bacterial strains
KR102850602B1 (en) * 2023-01-19 2025-08-26 재단법인 대구경북첨단의료산업진흥재단 Novel Lactic acid bacterium for preventing or treating bone disease and culture medium thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0127916D0 (en) 2001-11-21 2002-01-16 Rowett Res Inst Method
ES2895666T3 (en) 2006-10-27 2022-02-22 Capsugel Belgium Nv Hydroxypropylmethylcellulose hard capsules and manufacturing process
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
KR102661603B1 (en) * 2015-06-01 2024-04-29 더 유니버서티 오브 시카고 Treatment of cancer by manipulation of commensal microflora
HUE036362T2 (en) * 2015-11-20 2018-07-30 4D Pharma Res Ltd Preparations containing bacterial strains
EP3630942B1 (en) * 2017-05-24 2022-11-30 4D Pharma Research Limited Compositions comprising bacterial strain

Also Published As

Publication number Publication date
IL275949A (en) 2020-08-31
CL2020001888A1 (en) 2020-12-18
MA51613A (en) 2020-11-25
PH12020551080A1 (en) 2021-08-02
CN111629739A (en) 2020-09-04
US20210060095A1 (en) 2021-03-04
CA3088413A1 (en) 2019-07-25
EP3740218A1 (en) 2020-11-25
BR112020014676A2 (en) 2020-12-08
KR20200111183A (en) 2020-09-28
CO2020010013A2 (en) 2020-08-31
US20230048366A1 (en) 2023-02-16
JP2021516216A (en) 2021-07-01
MX2020007671A (en) 2020-09-14
TW201938180A (en) 2019-10-01
NI202000052A (en) 2021-01-20
WO2019141996A1 (en) 2019-07-25
AU2019210002A1 (en) 2020-08-13
US20240016861A1 (en) 2024-01-18

Similar Documents

Publication Publication Date Title
IL290149A (en) Combination therapy for cancer treatment
IL267795A (en) Combination therapy for the treatment of cancer
EP3407978A4 (en) Combination therapy for treating cancer
GB201903546D0 (en) Cancer treatment
IL275949A (en) Combination therapy for treating or preventing cancer
IL282093A (en) Combination therapy for cancer
SG11202103141YA (en) Combination therapy for the treatment of cancer
IL281439A (en) Combination therapy for treating blood cancer
IL266993A (en) Combination therapy for the treatment of cancer
IL276074A (en) Combination therapy for treating or preventing cancer
IL284162A (en) Combination therapy for the treatment of cancer
SG11202010528XA (en) Combinations for treating cancer
IL285466A (en) Cancer treatment
SG11202102492PA (en) Combination therapy for the treatment of prostate cancer
IL276073A (en) Combination therapy for treating or preventing cancer
IL288178A (en) Gmci and ddri combination therapy for treating cancer
IL275860A (en) Combination therapy for treating or preventing cancer
IL286680A (en) Medicament for treating cancer
IL278921A (en) Combination therapies for treating cancer
GB201819920D0 (en) Cancer treatment
IL253642A0 (en) Combination therapy for the treatment of cancer
GB201808628D0 (en) Combination therapy for treating or preventing cancer
GB201808631D0 (en) Combination therapy for treating or preventing cancer
GB201808632D0 (en) Combination therapy for treating or preventing cancer
GB201808636D0 (en) Combination therapy for treating or preventing cancer